Cancer immunoediting: from immunosurveillance to tumor escape
暂无分享,去创建一个
R. Schreiber | G. Dunn | A. Bruce | H. Ikeda | L. Old
[1] M. Burnet. Cancer—A Biological Approach , 1957, British medical journal.
[2] M BURNET,et al. Cancer—A Biological Approach* , 1957, British medical journal.
[3] T. Nash. Chemical Carcinogenesis , 1957, Nature.
[4] M. Burnet. IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.
[5] L. Old,et al. IMMUNOLOGY OF EXPERIMENTAL TUMORS. , 1964, Annual review of medicine.
[6] Old Lj,et al. Immunology of Experimental Tumors , 1964 .
[7] J. Miller,et al. Effect of Neonatal Thymectomy on the Induction of Sarcomata in C57BL Mice , 1965, Nature.
[8] Y. Nishizuka,et al. Enhancing Effect of Thymectomy on Hepatotumorigenesis in Swiss Mice following Neonatal Injection of 20-Methylcholanthrene , 1965, Nature.
[9] S. Flanagan,et al. 'Nude', a new hairless gene with pleiotropic effects in the mouse. , 1966, Genetical research.
[10] N. Trainin,et al. Enhancement of lung adenoma formation by neonatal thymectomy in mice treated with 7,12‐dimethylbenz(a)anthracene or urethan , 1967, International journal of cancer.
[11] E. M. Pantelouris,et al. Absence of Thymus in a Mouse Mutant , 1968, Nature.
[12] B. C. F. F. Israel Penn M.B.. Malignant Tumors in Organ Transplant Recipients , 1970, Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer.
[13] F. Burnet. The concept of immunological surveillance. , 1970, Progress in experimental tumor research.
[14] H. Kaplan. Role of Immunologic Disturbance in Human Oncogenesis: Some Facts and Fancies , 1971, British Journal of Cancer.
[15] R. Prehn. Perspectives on oncogenesis: does immunity stimulate or inhibit neoplasia? , 1971, Journal of the Reticuloendothelial Society.
[16] R. Gatti,et al. Occurrence of malignancy in immunodeficiency diseases: A literature review , 1971, Cancer.
[17] N. Burstein,et al. Neonatal Thymectomy and Non-viral Mammary Tumours in Mice , 1971, Nature.
[18] J. Daly,et al. Long-term spontaneous tumor incidence in neonatally thymectomized mice. , 1973, Journal of immunology.
[19] G. Klein. Immunological surveillance against neoplasia. , 1973, Harvey lectures.
[20] O. Stutman. Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.
[21] J. Rygaard,et al. Is immunological surveillance not a cell-mediated immune function? , 1974, Transplantation.
[22] J. Rygaard,et al. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. , 2009, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.
[23] R. Custer,et al. Spontaneous and induced tumor incidence in germfree "nude" mice. , 1975, Journal of the Reticuloendothelial Society.
[24] O. Stutman. Immunodepression and malignancy. , 1975, Advances in cancer research.
[25] L. Fatti,et al. Prostatic carcinoma. Some morphological features affecting prognosis , 1976, Cancer.
[26] N. Di Lorenzo,et al. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. , 1978, Journal of neurosurgery.
[27] R. Herberman,et al. Natural cell-mediated immunity. , 1978, Advances in cancer research.
[28] B. Giovanella,et al. The Nude Mouse in Experimental and Clinical Research , 1978 .
[29] O. Stutman. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. , 1979, Journal of the National Cancer Institute.
[30] C. Uyttenhove,et al. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice , 1980, The Journal of experimental medicine.
[31] Tumor antigens. , 1981, The New England journal of medicine.
[32] P. Davaris,et al. Prognostic significance of histologic host response in cancer of the large bowel , 1981, Cancer.
[33] C. Cohen,et al. Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response. , 1982, American journal of obstetrics and gynecology.
[34] M. Kripke,et al. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation , 1982, The Journal of experimental medicine.
[35] L. Thomas. On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.
[36] C. Cohen,et al. Histologic correlates of virulence in ovarian adenocarcinoma , 1982 .
[37] T. Hunig. T-cell function and specificity in athymic mice. , 1983, Immunology today.
[38] S. Ikehara,et al. Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[39] I. Weiler,et al. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency , 1986, Cell.
[40] J. Jass. Lymphocytic infiltration and survival in rectal cancer. , 1986, Journal of clinical pathology.
[41] J. Ravetch,et al. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10) , 1987, The Journal of experimental medicine.
[42] L. Sherman,et al. The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.
[43] R. Herberman,et al. Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.
[44] A. Macleod,et al. Cancer after transplantation. , 1988, BMJ.
[45] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[46] S. Ménard,et al. Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.
[47] E. Unanue,et al. Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid Mouse , 1991, Immunological reviews.
[48] V. Stewart,et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.
[49] K. Jauhiainen,et al. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. , 1992, European journal of cancer.
[50] P. Leder,et al. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.
[51] McGuire Wl,et al. Tumour Infiltrating Lymphocytes as an Independent Prognostic Factor in Transitional Cell Bladder Cancer , 1993 .
[52] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[53] R. Schreiber,et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.
[54] L. Koniaris,et al. Human Mig chemokine: biochemical and functional characterization , 1995, The Journal of experimental medicine.
[55] Eero Pukkala,et al. Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.
[56] B. Griffith,et al. Solid tumors after heart transplantation: lethality of lung cancer. , 1995, The Annals of thoracic surgery.
[57] I. Penn,et al. Sarcomas in organ allograft recipients. , 1995, Transplantation.
[58] G. Trinchieri. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.
[59] M. Mihm,et al. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[60] I. Svane,et al. Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[61] R. Zinkernagel,et al. Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.
[62] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[63] I. Penn. Malignant melanoma in organ allograft recipients. , 1996, Transplantation.
[64] H. Ljunggren,et al. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice , 1996, European journal of immunology.
[65] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[66] L. Old,et al. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[67] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[68] J. Darnell,et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[69] I. Svane,et al. MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice , 1997, Scandinavian journal of immunology.
[70] Aseem Kumar,et al. Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases , 1997 .
[71] S. Pestka,et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.
[72] D. Scadden. AIDS-related malignancies. , 1998, Current opinion in oncology.
[73] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[74] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[75] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[76] James G. Boyd,et al. Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.
[77] S. Jackson,et al. DNA double-strand break repair , 1999, Current Biology.
[78] A. Hayday. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. , 2000, Annual review of immunology.
[79] J. Trapani,et al. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.
[80] T. Blankenstein,et al. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.
[81] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[82] T. Mcclanahan,et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.
[83] J. Trapani,et al. Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.
[84] M. Smyth,et al. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.
[85] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[86] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[87] A. Diefenbach,et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.
[88] A. Hayday,et al. Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.
[89] M. Smyth,et al. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.
[90] Drew M. Pardoll,et al. Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.
[91] J. Trapani,et al. Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.
[92] Diego Piccioli,et al. Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells , 2002, The Journal of experimental medicine.
[93] G. Trinchieri,et al. Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.
[94] Giovanni Melioli,et al. Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells , 2002, The Journal of experimental medicine.
[95] Lloyd J. Old,et al. The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .
[96] M. Smyth,et al. Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.
[97] B. A. D. Luster. BIOCHEMICAL CHARACTERIZATION OF A y INTERFERON-INDUCIBLE CYTOKINE (IP-10) , 2003 .
[98] I. Penn. Posttransplant malignancies , 2004, World Journal of Urology.
[99] A. Wilde,et al. Now You See It, Now You Don't , 2004, Science's STKE.